SCHEMBL23498461

SCHEMBL23498461

O=Cc1sc2c(N(Cc3ccco3)C(=O)O)nc(Cl)nc2c1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.39
TSHR P16473 4/20 0.39
POLB P06746 2/20 0.39
ALDH1A1 P00352 5/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
MAPT P10636 4/20 0.38
ADORA2A P29274 2/20 0.38
ADORA1 P30542 1/20 0.38
CYP1A2 P05177 3/20 0.37
CYP2C19 P33261 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 2/20 0.35
THRB P10828 1/20 0.35
HTT P42858 2/20 0.35
ALOX15 P16050 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29998327 0.88 ADORA2A (0.35) LMNATSHRPOLBALDH1A1MEN1
SCHEMBL23498668 0.83 ADORA2A (0.34) LMNATSHRPOLBALDH1A1MEN1
SCHEMBL23498660 0.83 ADORA2A (0.34) LMNATSHRPOLBALDH1A1MEN1
SCHEMBL23498663 0.83 ADORA2A (0.34) LMNATSHRPOLBALDH1A1MEN1
SCHEMBL23498686 0.81 LMNA (0.43) LMNATSHRPOLBALDH1A1MEN1
SCHEMBL23498508 0.78 ALDH1A1 (0.40) LMNATSHRPOLBALDH1A1MEN1
SCHEMBL23498841 0.78 TP53 (0.37) LMNATSHRPOLBALDH1A1MEN1
SCHEMBL23498695 0.76 MEN1 (0.44) LMNATSHRPOLBALDH1A1MEN1
SCHEMBL29997935 0.75 ADORA2A (0.31) LMNAALDH1A1MEN1KMT2AADORA2A
SCHEMBL23498859 0.75 TSHR (0.45) LMNATSHRPOLBALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230057568-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2023-02-23 US disclosed
WO-2021118929-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2021-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230057568-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA SNRPB2, SYNCRIP, HNRNPUL2 LMNA 292/4885TSHR 2908/4885POLB 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.